Opposing Effects of Platelet-activating Factor and Lyso-Platelet-activating Factor on Neutrophil and Platelet Activation

Emily J. Welch, Ram P. Naikawadi, Zhenyu Li, Phoebe Lin, Satoshi Ishii, Takao Shimizu, Chinnaswamy Tiruppathi, Xiaoping Du, Papasani V. Subbaiah, Richard D. Ye

Department of Pharmacology (E.J.W, R.P.N., Z.L., P.L., C.T., X.D., R.D.Y.) and Department of Medicine (P.V.S.), University of Illinois College of Medicine, Chicago, IL 60612, U.S.A.; and Department of Biochemistry and Molecular Biology, University of Tokyo, Tokyo, Japan (S.I., T.S.)
Running title: LysoPAF and PAF have opposing effects

Correspondence: Richard D. Ye, University of Illinois College of Medicine, 835 South Wolcott Avenue, M/C 868, Chicago, IL 60612. Tel. (312) 996-5087, Fax: (312) 996-7857. E-mail: yer@uic.edu

Number of Text Pages: 14
Number of Tables: 0
Number of Figures: 6
Number of References: 40
Abstract Word Count: 208
Introduction Word Count: 476
Discussion Word Count: 1188

Abbreviations: PLA₂, phospholipase A₂; PAF, platelet-activating factor (1-O-hexadecyl-2-acetoyl-sn-glycero-3-phosphocholine); lysoPAF, 1-O-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine; GPCR, G-protein coupled receptor; PKA, protein kinase A; PAFR, platelet-activating factor receptor; fMLF, N-Formyl-L-methionyl-L-leucyl-L-phenylalanine; HPMECs, human pulmonary microvessel endothelial cells; PAF-AH, platelet-activating factor acetylhydrolase; PAF-AT, platelet-activating factor acetyltransferase; TER, transendothelial Electrical Resistance; SQ22536, 9-(tetrahydro-2-furyl)adenine, KT5720, (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3’,2’,1’-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid hexyl ester; H-89, N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride CTx, Cholera Toxin; PTx, pertussis toxin; Rₓ, retardation factor; IBMX, 3-Isobutyl-1-methylxanthine.
Platelet-activating factor (PAF) is a potent, bioactive phospholipid that acts on multiple cells and tissues through its G protein-coupled receptor (GPCR). PAF is not stored, but rapidly generated via enzymatic acetylation of the precursor, lysoPAF. The bioactivity of PAF is effectively and tightly regulated by PAF acetylhydrolases, which convert PAF back to lysoPAF. Previous studies report that lysoPAF is an inactive precursor and metabolite of PAF. However, lysoPAF has not been carefully studied in its own context. Here we report that lysoPAF has an opposing effect of PAF in the activation of neutrophils and platelets. Whereas PAF potentiates neutrophil NADPH oxidase activation, lysoPAF dose-dependently inhibits this function. Inhibition by lysoPAF is not affected by the use of a PAF receptor antagonist or genetic deletion of the PAF receptor gene. The mechanism of lysoPAF-mediated inhibition of neutrophils involves an elevation in the intracellular cAMP level, and pharmacological blockade of adenylyl cyclase completely reverses the inhibitory effect of lysoPAF. In addition, lysoPAF increases intracellular cAMP levels in platelets and inhibits thrombin-induced platelet aggregation, which can be reversed by inhibition of PKA. These findings identify lysoPAF as a bioactive lipid with opposing functions of PAF, and suggest a novel and intrinsic regulatory mechanism for balance of the potent activity of PAF.
INTRODUCTION

Platelet-activating factor (PAF, 1-O-hexadecyl-2-acetoyl-sn-glycero-3-phosphocholine) is one of the most active lipid species identified to date. It was first discovered in the early 1970’s as a bioactive lipid generated by basophils capable of inducing platelet aggregation and anaphylaxis (Benveniste et al., 1972). Specifically, levels of PAF have been shown to directly correlate to the severity of anaphylaxis (Vadas et al., 2008). In addition, PAF plays important roles in inflammation. PAF is produced by a variety of cells, including neutrophils. These effects are thought to be mediated by a G protein-coupled PAF receptor (Honda et al., 1991; Hwang et al., 1983).

Because of the potent and sometimes deleterious biological effects, PAF synthesis is tightly regulated. PAF is not stored in large amounts in the cell, and its production is induced by proinflammatory factors (Szabo et al., 1993). The induced synthesis of PAF involves the de novo pathway and remodeling pathway, the latter being responsible for the majority of PAF induced by inflammatory stimuli (Reinhold et al., 1989). In this process, PLA₂ cleaves membrane phospholipids at the sn-2 position and yields several lipid products, including lysoPAF (1-O-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine). The highly specific PAF-acetyltransferase (PAF-AT) then adds an acetyl group to the sn-2 position to yield PAF (Shindou et al., 2007). PAF is subsequently degraded through removal of the acetyl group by PAF-acetylhydrolases (PAF-AH) (Karasawa et al., 2003). The PAF-AH mediated conversion to lysoPAF is a primary pathway for PAF inactivation, and there have been efforts in the exploration of PAF-AH as a potential therapeutic agent (Arakawa et al., 2005; Gomes et al., 2006; Quarck et al., 2001). The levels of PAF-AH are inversely correlated with the severity of
anaphylaxis (Vadas et al., 2008), and the administration of human recombinant PAF-AH can inhibit several mouse models of anaphylaxis (Fukuda et al., 2000).

Although lysoPAF is thought to lack bioactivity and is often used as a control in experiments exploring PAF function, it has not been carefully studied in its own context. Given that lysoPAF levels are inversely related to those of PAF, and that it is a metabolite as well a precursor of PAF, there seems to be a need to understand any potential activity that this lipid may have. Furthermore, the potential therapeutic use of recombinant PAF-AH in humans requires a comprehensive understanding of the cellular functions of the lipid produced by this enzyme. In the course of a study of neutrophil activation by bioactive lipids, we found that lysoPAF exhibits an inhibitory effect on neutrophil superoxide production. Further investigation has led to the discovery of lysoPAF-induced intracellular cAMP production as a potential mechanism for its inhibitory effect. Moreover, treatment of platelets with lysoPAF reduces their aggregation following low dose thrombin stimulation. These data suggest that lysoPAF balances some of the bioactivities of PAF, and the beneficial effects of PAF-AH may be attributed in part to this negative regulatory function of lysoPAF.

MATERIALS AND METHODS

Materials. Synthetic lysoPAF (16:0, 18:0) and PAF (16:0) were obtained from Avanti Polar lipids (Alabaster, AL). The lipids were dissolved in 50% (v/v) EtOH/H2O. Percoll was purchased from Amersham Biosciences (Piscataway, NJ). The PKA inhibitors H-89 and KT5720, and the adenylyl cyclase inhibitor SQ22536 were purchased from Calbiochem (San Diego, CA). The PAFR antagonist SR 27417 is a generous gift from Dr. J. M. Herbert (Sanofi-
Aventis, France). Isoluminol, C5a, fMLF and cholera toxin were obtained from Sigma-Aldrich (St. Louis, MO). Horseradish peroxidase (HRP) was acquired from Invitrogen.

**Preparation of neutrophils.** Human peripheral blood was collected from healthy donors by venipuncture, using a protocol approved by the Institutional Review Board at University of Illinois at Chicago. Acid citrate dextran was used as anti-coagulant. Neutrophil isolation was carried out using discontinuous Percoll gradient (Lin et al., 2005). For preparation of mouse neutrophils, mice were anesthetized with CO₂ and sacrificed by cervical dislocation. Femurs and tibias of wild type and PAFR⁻/⁻ littermate mice, on a C57Bl6 background, were isolated and placed in HBSS-Prep (HBSS, 0.5% FBS, 10mM HEPES, and 1% Glucose). Bone marrow was then harvested, marrow was disaggregated, and then cells were separated by centrifugation using a discontinuous density gradient consisting of 3 ml NycoPrep 1.077 (Axis-Shield) underlayed with 72% Percoll (Amersham Biosciences). Neutrophils were collected at the NycoPrep-Percoll interface, and washed 2x with HBSS-Prep. Final resuspension was in 0.5% BSA in RPMI medium. Purity of neutrophils was consistently at 80% or above, as determined by FACS scatter, Wright staining, and Hemavet (Drew Scientific).

**Preparation of human platelets.** Blood was taken as described above with approval. Acid citrate dextran was used as an anti-coagulant. Platelet isolation was performed as described previously (Li et al., 2006).

**Superoxide generation.** Human PMN superoxide generation was measured by isoluminol-enhanced chemiluminescence as described previously (Lin et al., 2005). Chemiluminescence was measured every minute using a Wallac Multilabel Counter plate reader (Perkin Elmer Life Sciences, Boston, MA). Unstimulated controls were recorded.
simultaneously. Alternatively, some samples were pre-incubated with lipid or inhibitors prior to stimulation.

**Endothelial Cell Culture and transendothelial electrical resistance measurement.**

Human pulmonary microvessel endothelial cells (HPMECs) were purchased from Sciencell (Carlsbad, CA), and were cultured in endothelial basal medium (EBM-2) supplemented with EGM-2MV from Lonza (Walkersville, MD). HPMECs were plated on gelatin-coated Electric cell-substrate impedance sensing (ECIS) 8 well 10 electrode arrays from Applied Biophysics (Piscataway, NJ) until confluency prior to experiment. Isolated human neutrophils (4x10^4 per well) were pre-incubated with vehicle, lysoPAF (1μM) or PAF (1μM) for ten min prior to addition to endothelial cell monolayers. The electrode was then connected and the resistance was monitored as described previously (Tiruppathi et al., 1992). Then, fMLF (1 μM) was added to indicated samples and the recording continued for a further 5 hours.

**Calcium mobilization.** Increase in intracellular calcium was detected using Indo-1/AM-labeling of human PMNs kept in a 0.5% BSA/HBSS buffer as described previously (He et al., 2003).

**cAMP assay.** cAMP was measured using a competitive enzyme-linked immunosorbent assay (Biomol) as described previously (Lin et al., 2005).

**Platelet aggregation.** Platelet aggregation was measured as described previously (Li et al., 2006). Briefly, washed human platelets, at a concentration of 3x10^8/mL, were pre-treated with lysoPAF (10 nM to 1 μM) or control for 2 minutes, then stimulated with α-thrombin from Enzyme research laboratories (South Bend, IN).

**Statistical analysis.** Data were analyzed by unpaired student t test using Prism (ver.4.0) software from GraphPad, San Diego, CA.
RESULTS

LysoPAF inhibits neutrophil NADPH oxidase activation and neutrophil-induced vascular damage. Treatment of human neutrophils with PAF does not lead to significant superoxide production. Instead, the cells are sensitized and respond more potently to subsequent stimulation with another agonist (Dewald and Baggioiini, 1985; Vercellotti et al., 1988). This “priming” effect is evident in human neutrophils first incubated with PAF and then stimulated with fMLF, a full agonist of neutrophils (Figure 1A). In PAF-treated neutrophils, fMLF (1 μM)-induced superoxide production was 2.85-fold higher than the level in buffer-treated cells (p < 0.01), based on isoluminol-enhanced chemiluminescence (ECL) (Figure 1A, 1B). LysoPAF, widely considered a non-active PAF metabolite and precursor, is often used as a negative control in studies of the bioactivity of PAF. When superoxide production in lysoPAF-treated neutrophils was set as baseline (open bar in Figure 1B), the “priming” effect of PAF became more evident (a 6.92-fold increase) following fMLF stimulation (p < 0.01). LysoPAF (1 μM) caused a 57% reduction of the fMLF-induced superoxide production when compared to buffer-treated neutrophils under the same experimental conditions (Figure 1A, 1B). These results suggest that lysoPAF is bioactive and produces an inhibitory effect on fMLF-induced neutrophil superoxide production.

The alkyl group in PAF and lysoPAF is connected through an ether linkage at the C1 position to a carbon chain of variable lengths. In the above study, 16:0 PAF and lysoPAF was used. To determine whether the length of the carbon chain affects the bioactivity of lysoPAF, we examined 18:0 lysoPAF from the same source and found it to be equally effective in the inhibition of fMLF-induced superoxide production (Figure 1C). Next, we determined the potency of PAF and lysoPAF in superoxide production assays. Both PAF and lysoPAF
exhibited bioactivity at concentrations as low as 10 nM. The opposing effects of PAF and lysoPAF on superoxide production continue to increase up to the concentration of 1 μM (Figure 1D).

Neutrophil activation can lead to microendothelial injury, manifested as increased endothelial permeability and loss of barrier function. These changes are seen during Gram-negative bacterial infection and in numerous inflammatory disorders such as adult respiratory distress syndrome (Lee and Downey, 2001). In addition, pulmonary edema is one of the hallmarks of anaphylaxis. We determined the effects of PAF and lysoPAF on neutrophil-dependent changes of endothelial permeability by measuring transendothelial electrical resistance (TER), a well established in vitro assay of endothelial barrier function (Furie et al., 1984; Tiruppathi et al., 1992). In this assay, changes in TER reflect the integrity of the endothelial monolayer, which is compromised in the presence of reactive oxygen species from activated neutrophils. As shown in Figure 2A, fMLF stimulation of neutrophils caused a decrease in TER over time, and this change was further enhanced by pretreatment of neutrophils with PAF (1 μM). In contrast, lysoPAF used at the same concentration significantly reduced the fMLF-stimulated decrease in TER while having no significant effect on TER when applied alone (Figure 2B). These results suggest a potential function of lysoPAF in preventing neutrophil-mediated endothelial injury.

LysoPAF does not block the fMLF receptor. Inhibition of fMLF-stimulated superoxide generation could occur at multiple steps. To identify the related mechanisms, we first examined whether lysoPAF could block fMLF interaction with the formyl peptide receptor (FPR). One of the proximal signaling events downstream of the activated FPR is mobilization of intracellular Ca²⁺. Neutrophils were loaded with Indo-1/AM, then either treated with lysoPAF or
with vehicle control before stimulation with fMLF (Figure 3A). The results indicated that lysoPAF did not induce Ca\(^{2+}\) mobilization in neutrophils, and treatment of neutrophils with lysoPAF had no effect on the fMLF-induced Ca\(^{2+}\) mobilization. These results preclude that lysoPAF blocks the fMLF interaction to FPR.

To rule out the possibility that the inhibitory effect of lysoPAF is specifically targeted at FPR signaling pathways, we investigated whether lysoPAF affects C5a signaling. Stimulation of neutrophils with C5a caused superoxide production (Figure 3B, filled squares). In cells treated with PAF, the C5a-induced superoxide production was markedly increased (filled circles). In contrast, lysoPAF treatment markedly decreased the C5a-induced superoxide production (filled triangles). Therefore, the inhibitory effect of lysoPAF is not confined to one chemoattractant receptor.

**The inhibitory effect of lysoPAF is independent of the PAF receptor.** Because of the structural similarity between PAF and lysoPAF, we investigated whether the inhibitory effects of lysoPAF are mediated through the PAF receptor. When neutrophils were exposed to both PAF and lysoPAF at equal molar concentrations, the effect of the individual lipids was negated (Figure 4A). To determine whether lysoPAF directly affects PAF receptor (PAFR)-mediated signaling, we conducted a Ca\(^{2+}\) mobilization assay, in which neutrophils were treated with lysoPAF before measurement of PAF-induced increase in intracellular Ca\(^{2+}\) concentration. As shown in Figure 4B, lysoPAF did not induce Ca\(^{2+}\) mobilization, and it produced no effect on PAF-induced Ca\(^{2+}\) mobilization. We also used a PAF receptor antagonist, SR27417 (Herbert et al., 1991), to determine whether blocking PAFR could alter the effects of PAF and lysoPAF on fMLF-induced superoxide production. Neutrophils were incubated in the presence or absence of SR27417 (10 nM) and either PAF or lysoPAF, and then stimulated with fMLF. As shown in
Figure 3C, SR27417 abrogated PAF priming in the neutrophils, but did not change the inhibitory effect of lysoPAF. This result argues against the notion that lysoPAF competes with PAF in utilizing PAFR, although it does not rule out the possibility that lysoPAF may interact with the receptor at a site different from the PAF binding site. This latter possibility was tested using neutrophils derived from PAFR knockout mice (Ishii et al., 1998). As shown in Figure 4D, genetic deletion of the PAFR gene abolished the priming effect of PAF, but did not alter the inhibitory effect of lysoPAF, on fMLF-induced superoxide production. Taken together, results from these experiments indicate that inhibition by lysoPAF is independent of PAFR.

**LysoPAF activates adenylyl cyclase and increases intracellular cAMP concentration in neutrophils.** Molecular characterization of PAFR has led to the identification of its signaling pathways that include functional coupling to the Gq class of G proteins, activation of PLCβ, and induction of second messengers inositol (1,4,5)-trisphosphate and diacyl glycerol (Honda et al., 2002). PAFR also couples to the Gi class of G proteins that mediate the chemotactic and cross-regulatory signals and also contribute to the activation of PLCβ and exocytosis in transfected RBL-2H3 cells with the G proteins fused to the PAFR (Brown et al., 2006). As a result, PAF stimulation leads to Ca²⁺ mobilization in neutrophils. We have shown that stimulation of neutrophils with lysoPAF does not cause increase in intracellular Ca²⁺ concentration (Figure 4B), suggesting differences between PAF and lysoPAF in the activation mechanism and the utilization of downstream effectors. Because several anti-inflammatory molecules stimulate the adenylyl cyclase - cAMP- signaling pathway (Fantone et al., 1983; Fantone et al., 1984; Rivkin and Becker, 1976), we tested whether lysoPAF could activate this pathway and increase cAMP concentration in human neutrophils. As shown in Figure 5A, stimulation of neutrophils with lysoPAF resulted in dose-dependent increases in intracellular cAMP concentrations that reached
up to 2-fold above baseline. It is possible that lysoPAF activates a G\(\alpha_s\)-coupled receptor, leading to cAMP production. This is suggested by the observation that cholera toxin, which ADP ribosylates and activates G\(\alpha_s\), increased cAMP level to the same extent as in lysoPAF-stimulated cells (Figure 5B). Likewise, cholera toxin dose-dependently inhibited fMLF-stimulated superoxide production (Figure 5C). Pertussis toxin, which ADP ribosylates the G\(\alpha_i\) proteins and interferes with G\(\alpha_i\) – receptor interaction, had no effect on lysoPAF-induced elevation of cAMP concentration.

The involvement of an adenylyl cyclase is suggested by the results from experiments using the adenylyl cyclase inhibitor SQ22536 (9-(tetrahydro-2-furyl)adenine) (Graber and Hawiger, 1982), which dose-dependently reversed the inhibitory effect of lysoPAF on the production of superoxide (Figure 5D). Protein kinase A (PKA), a key kinase activated by cAMP, also plays a role in the inhibition by lysoPAF. Using the PKA inhibitor H-89, we observed a partial restoration (p < 0.05) of superoxide production in fMLF-stimulated neutrophils that were pretreated with lysoPAF (Figure 5E). This result is confirmed in a parallel experiment using another PKA inhibitor, KT5720, which produced similar effect in reversal of the effect of lysoPAF. These results indicate that lysoPAF signaling involves adenylyl cyclase-mediated generation of cAMP, and that PKA contributes to the inhibitory effect of lysoPAF.

**LysoPAF induces cAMP elevation in platelets and inhibits platelet aggregation.** In addition to neutrophils, other blood cells including platelets are involved in inflammatory responses. PAF was originally named for its activating effect on platelets (Benveniste et al., 1972). However, a bioactivity of lysoPAF on platelets has not been reported. We conducted experiments to determine whether lysoPAF could affect the intracellular cAMP levels in platelets, and if treatment of platelets with lysoPAF would affect its activation. In washed
human platelets, lysoPAF induced a significant increase in cAMP levels (p < 0.01) (Figure 6A), whereas PAF does not have an effect on the intracellular cAMP levels in platelets under the same experimental conditions. Similar to neutrophils, cAMP inhibits many activation processes in platelets, including platelet aggregation (Salzman et al., 1972). We therefore tested whether lysoPAF-treated platelets display changes in agonist-induced platelet aggregation. When washed platelets were pre-incubated with lysoPAF and then stimulated with α-thrombin (0.03U/ml), a lysoPAF dose-dependent inhibition in platelet aggregation was observed (Figure 6B). Also similar to neutrophils, PKA is known to be involved in downstream signaling of cAMP. The inhibitory effect of lysoPAF on thrombin-induced platelet aggregation is partially reversed by the PKA inhibitors H-89 and KT5720 (Figure 6C).

DISCUSSION

Results from this study demonstrate that lysoPAF is bioactive and produces an effect opposite of that of PAF in neutrophil superoxide production. Whereas PAF potentiates NADPH oxidase activation and superoxide production, lysoPAF inhibits this function. The inhibitory effect of lysoPAF does not depend on PAFR, and is not limited to a particular agonist such as fMLF or one cell type such as neutrophils. In our experiments, the C5a-stimulated neutrophil superoxide production and thrombin-induced platelet aggregation are also inhibited by lysoPAF. These observations are novel, and provide evidence for a possible function of lysoPAF in balancing the proinflammatory activities of PAF. While PAF plays important roles in regulating cellular functions, its proinflammatory activities require temporal regulatory mechanisms including induced synthesis and efficient degradation. Therefore, enzymes responsible for PAF synthesis and degeneration, mainly the PAF-ATs and PAF-AHs, are potential targets of
therapeutic intervention. Results from the current study suggest that PAF-AHs, in addition to removing PAF from circulation and tissues, may at the same time create a bioactive molecule with opposing functions, thereby effectively negating the bioactivity of PAF. It is likely that the inhibitory effects of lysoPAF on neutrophils and platelets contribute to the anti-inflammatory functions of PAF-AHs (Henderson et al., 2000).

Previous studies of the bioactivity of PAF often included lysoPAF as a negative control. Other reports showed that lysoPAF displayed PAF-like activities in stimulating DNA synthesis in smooth muscle cells (Chai et al., 2000) and microvascular leakage when administered to guinea pigs by inhalation (Sakamoto et al., 1993). These PAF-like activities, including the ability to induce Ca\(^{2+}\) mobilization, were blocked by PAFR antagonists, indicating that they are mediated by the identified PAFR (Sakamoto et al., 1993). Marathe and colleagues have shown that treatment of the bioactive lysoPAF and lysoPC with PAF-AH or with saponification abolishes the activities of these lysophospholipids, indicating that these activities come from contaminating phospholipids (Marathe et al., 2001). Before chemically synthesized PAF became widely available, many studies were conducted using PAF isolated from crude methanol extracts of cells or egg yolk, and those studies were prone to contamination with PAF-like phospholipids. The same methods apparently contributed to the identification of lipids migrating with a similar \(R_f\) as PAF on thin-layer chromatography and containing both platelet-activating and neutrophil-inhibiting properties (O'Donnell et al., 1981). To eliminate contaminations with other phospholipids, in this study we used synthetic lysoPAF and PAF from the same source, and prepared stock solutions for both lipids using exactly the same method. Experiments that compared lysoPAF and PAF were strictly carried out in parallel. Our study has shown dose-dependent inhibition of neutrophil NADPH oxidase activation by lysoPAF, with minimal active
concentrations as low as 10 nM. Under the same experimental conditions, the potentiation effect of PAF was detectable.

The exact mechanism by which lysoPAF exerts its bioactivity is still unknown. As the first step towards an answer to this question, we determined whether elevation of intracellular cAMP level contributes to the inhibitory effects of lysoPAF. Our results confirmed that lysoPAF, but not PAF, was able to stimulate an increase in cAMP levels in both neutrophils and platelets. Moreover, pharmacological inhibition of PKA, an effector of cAMP, partially reversed the inhibitory effect of lysoPAF, indicating that the cAMP-PKA pathway is involved, but PKA-independent mechanism may also exist. We also found that treating neutrophils with SQ22536, an inhibitor of adenylyl cyclase, dose-dependently reversed the inhibitory effect of lysoPAF on superoxide generation. These results confirm that adenylyl cyclase-mediated production of cAMP is key to the inhibitory activity of lysoPAF. These effects are not likely the results of non-specific actions of the inhibitors on other kinases, most of which are important for neutrophil NADPH oxidase activation and platelet aggregation.

We hypothesize that lysoPAF activates adenylyl cyclase through either one or both of the following pathways. First, lysoPAF may bind to a receptor that couples to the Gs class of G proteins. Because Goαs activates adenylyl cyclase, lysoPAF binding to this receptor leads to increased cAMP production. This is likely given the emergence of an increasing number of GPCRs for bioactive lipids (Im, 2004). Our study using cholera toxin, which activates Goαs, produced similar effect in the elevation of cAMP levels and inhibition of superoxide generation as seen in lysoPAF-stimulated cells. To determine which receptor(s) is activated by lysoPAF, we have conducted an exhaustive search of the existing GPCR database and identified 28 receptors that are related in sequence to known lipid receptors. These receptors were
individually analyzed in transfected cells for their abilities to mediate lysoPAF-induced increase in intracellular cAMP, CREB-driven luciferase reporter expression, and calcium mobilization. G2A has been shown to mediate the bioactivity of lysoPC (Lin et al., 2005; Wang et al., 2005), although it lacks certain pharmacological properties of a receptor such as direct binding of lysoPC (Kabarowski et al., 2001; Witte et al., 2005). When tested in our assays, G2A and structurally similar receptors such as GPR4, TDAG8 and OGR1, did not respond significantly to lysoPAF stimulation (Supplemental Table I). Other GPCRs tested also failed to respond to lysoPAF in these functional assays. Therefore, screening of additional GPCRs will be necessary to further test the hypothesis. We noticed that fMLF, which activates a Gi-coupled receptor FPR, is reported to enhance intracellular cAMP levels through a pertussis toxin-sensitive mechanism (Ali et al., 1998). However, fMLF also stimulates Ca\(^{2+}\) flux whereas lysoPAF does not, indicating that lysoPAF does not activate the same signaling pathway that is induced by fMLF. Nevertheless, expanding the search to other GPCRs may be beneficial to understanding of how lysoPAF induces cAMP elevation. The second possible mechanism for the inhibitory effect of lysoPAF involves direct activation of adenylyl cyclase. To date, ten isoforms of transmembrane adenylyl cyclase have been identified (Hurley, 1999). Adenylyl cyclase isoform 1 expression is restricted to the brain. Isoforms 6 and 7 are ubiquitously expressed in cells and tissues. We have tested several other cell types, including HPMECs, which were unable to respond to lysoPAF with increased cAMP levels (data not shown). Therefore, it is unlikely that the candidate is a ubiquitously expressed isoform of adenylyl cyclase. Store operated calcium channels are known to activate adenylyl cyclase isoforms 3 and 8; however we observed no changes in calcium levels in cells treated with lysoPAF. A further analysis is required to more carefully examine these cyclase isoforms.
In summary, results from the current study identify lysoPAF as a bioactive lipid with inhibitory functions in neutrophil NADPH oxidase activation and platelet aggregation. This novel finding may create an opportunity to investigate the biological functions of PAF-AHs in regulating the activities of PAF. Because lysoPAF is a precursor as well as metabolite of PAF, its tissue concentration is regulated by the presence of enzymes in the PAF remodeling pathway. Recent cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase (Shindou et al., 2007) and clinical correlation between lowered PAF-AH concentration and severity of anaphylaxis (Vadas et al., 2008) are expected to promote continued exploration of PAF-AH and related pathways. The discovery of lysoPAF as having opposite activities of PAF in the functional assays performed in this study may contribute to a better understanding of these phospholipids for their functions in human physiology.

ACKNOWLEDGEMENTS

The authors would like to thank Dr. Jean-Marc Herbert for the gift of SR27417, Dr. Guy Le Breton and Dr. Tohru Kozasa for suggestions on cAMP assays, Dr. Feng Qian for assistance with blood cell preparation, Fumie Hamano for technical assistance in receptor screening assays, and members of the Ye Laboratory for helpful discussions.
REFERENCES


MOL #51003


MOL #51003


This work was supported in part by NIH grants AI033503 and HL077806. E.J.W. is a recipient of a Predoctoral Fellowship from American Heart Association, Midwest Chapter.

Request for reprints should be sent to: Richard D. Ye, University of Illinois College of Medicine, 835 South Wolcott Avenue, M/C 868, Chicago, IL 60612. Tel. (312) 996-5087, Fax: (312) 996-7857. E-mail: yer@uic.edu
FIGURE LEGENDS

Fig. 1. PAF and lysoPAF differentially regulate fMLF-induced neutrophil NADPH oxidase activation. A, Detection of fMLF-induced superoxide generation as a function of time. CPS, counts per second of chemiluminescent light emitted. Isolated human neutrophils (5 x 10^5 per sample) were pre-incubated with indicated lipid (1 μM) or vehicle for 5 min prior to stimulation with 1 μM fMLF. Shown is a set of representative tracings from one of the 3 experiments that produced similar results. B, Data from all 3 experiments were quantified based on integrated areas under curve (AUC), and then expressed as percent of fMLF-induced response using the condition without lipid pretreatment as 100%. C, Comparison of the effects of lysoPAF pretreatment, using two lysoPAF species with different chain lengths (16:0, 18:0), on fMLF-induced superoxide production in neutrophils from different donors (n=3). D, Dose response of lysoPAF and PAF in fMLF-induced superoxide generation. Shown is a representative set of data, as mean ± SEM, from 1 of the 3 experiments that produced similar results.

Figure 2. PAF- and lysoPAF-treated neutrophils affect endothelial barrier function. A, HPMEC were grown to confluence on a gold electrode. Human neutrophils (4 x 10^4) were pre-incubated with 1 μM of the indicated lipid or vehicle control for 10 min, added to the electrode well, and stimulated with 1 μM fMLF. The changes in transendothelial electrical resistance (TER) were recorded over time. Data shown are from one representative experiment, chosen from a total of four similar experiments. No significant changes in TER were observed with PAF or lysoPAF in the absence of PMN (data not shown). B, The peak values at the 4 h time point of the above experiments are shown as mean ± SEM, based on 4 separate experiments. ns, not significant, *, p < 0.05, ***, p< 0.001.
Figure 3. The effect of lysoPAF is not mediated through inhibition of the fMLF receptor or confined to fMLF stimulation. A, Real-time measurement of Ca^{2+} mobilization in human neutrophils stimulated with 1 μM fMLF, in the presence or absence of 1 μM lysoPAF. B, Detection of the effects of lysoPAF and PAF on C5a-induced superoxide generation. CPS, counts per second of chemiluminescent light emitted. Isolated human neutrophils (5 X 10^5 per sample) were pre-incubated with the indicated lipid (1 μM) or vehicle (same concentration of ethanol, 0.025% v/v) for 5 min prior to stimulation with 100 nM C5a. Shown is a representative set of tracings from one of the three independent experiments, each produced similar results.

Figure 4. The inhibitory effect of lysoPAF is not mediated through the PAF receptor. A, human neutrophils (5 x 10^5 per sample) were incubated with the indicated lipid(s) (1 μM each) for 5 min prior to stimulation with 1 μM of fMLF. The changes in superoxide generation, expressed as integrated area under curve (AUC) are shown, with fMLF-induced response in the absence of lipid set as 100%. Data shown are mean ± SEM from 3 independent experiments. B, Real-time measurement of calcium mobilization in human neutrophils loaded with Indo-1/AM and stimulated with 1 μM PAF, or with 1 μM lysoPAF and then PAF. A representative set of tracings, from a total of 3 experiments, is shown. C, Superoxide generation was assessed in neutrophils treated for 5 min with the PAFR antagonist SR27417 (10 nM) prior to addition of PAF or lysoPAF (1 μM) or vehicle. Cells were then stimulated with fMLF (1 μM) and production of superoxide was measured over time. Data procession and presentation are similar to A. D, mouse neutrophils (1x10^6 per sample) isolated from PAFR^{+/+} or PAFR^{-/-} mice were incubated with indicated lipid for 5 min prior to stimulation with fMLF (1 μM). Integrated AUC was calculated for each mouse and data (mean ± SEM) expressed as percent of fMLF stimulation for each experiment (n=3).
**Fig. 5. LysoPAF activates the adenylyl cyclase–cAMP–PKA pathway.**  
*A*, human neutrophils were incubated with lysoPAF at different concentrations, or with PAF at 1 μM, for 5 min in the presence of the phosphodiesterase inhibitor IBMX. The cells were lysed, and cAMP was assayed by competitive immunoassay. Shown is a representative experiment of 3 that produced similar results.  
*B*, cAMP measurement of human neutrophils in the presence or absence of lysoPAF (1 μM, 5 min), CTx (1 μg/mL, 1 h with or without lysoPAF), or pertussis toxin (0.5 μg/mL, 1 h with or without lysoPAF (1 μM), in the presence of IBMX. cAMP was measured as described above. Shown are data from 2 experiments, normalized based on non-stimulated controls.  
*C*, Superoxide generation in the presence or absence of increasing concentrations of CTx, in the presence or absence of 1 μM lysoPAF. Human neutrophils were incubated with CTx for 1 h prior to addition of 1 μM lysoPAF for 5 min, then stimulated with 1 μM fMLF. Data are shown as % relative to fMLF-induced superoxide generation without lysoPAF, and are based on 2 different donors.  
*D*, Superoxide generation in the presence or absence of increasing concentrations of the adenylyl cyclase inhibitor SQ22536. Human neutrophils were incubated with indicated dose of SQ22536 or vehicle for 10 min prior to addition of lysoPAF (1 μM) for 5 min. Data are shown as % relative to fMLF-induced superoxide generation without lysoPAF or SQ22536, using neutrophils from 3 different donors.  
*E*, Superoxide generation was assessed in neutrophils treated with or without the PKA inhibitors H-89 (5 μM) or KT5720 (5 μM) prior to addition of lysoPAF (1 μM) or vehicle. The fMLF (1 μM) induced superoxide generation was measured, and expressed as percent change relative to superoxide generation in the absence of inhibitor and lysoPAF. Data shown are mean ± SEM based on 3 independent experiments.
Figure 6. LysoPAF induces cAMP elevation in platelets and suppresses thrombin-
induces platelet aggregation. A, human platelets (3 x 10⁸ /ml) were incubated with the
indicated lipid (1 μM) for 2 min. Cells were lysed in IBMX-containing buffer, and cAMP was
assayed by competitive immunoassay. Data shown are mean ± SEM and are representative of 3
experiments with similar results. B, Thrombin-induced platelet aggregation in the absence or
presence of lysoPAF. Human platelets were incubated with the indicated concentrations of
lysoPAF for 2 min prior to stimulation with α-thrombin (0.03 U/mL) at 37°C under stirring
conditions. Platelet aggregation, measured by light transmission, was determined over time. C,
Thrombin-induced platelet aggregation in the absence or presence of the PKA inhibitors H-89 (5
μM) or KT5720 (5 μM), prior to stimulation with vehicle or lysoPAF (1 μM). Platelet
aggregation was measured as in B. Data shown are representative of 2 independent experiments
with similar results.
Fig 5

A

![Bar chart showing cAMP levels for different lipids (nM) with vehicle, lysoPAF, and PAF treatments.](molpharm.png)

B

![Bar chart showing cAMP fold change for different CTx and PTx concentrations with vehicle and 1 μM lysoPAF treatments.](molpharm.png)

C

![Bar chart showing superoxide levels for different CTx ng/mL concentrations with vehicle and 1 μM lysoPAF treatments.](molpharm.png)

D

![Bar chart showing superoxide levels for different SQ22536 (μM) concentrations with vehicle and 1 μM lysoPAF treatments.](molpharm.png)

E

![Bar chart showing superoxide levels for different fMLF (1 μM) concentrations with vehicle and 1 μM fMLF treatments.](molpharm.png)